Alvotech shares are trading lower after the FDA issued a complete response letter to second application for AVT02, biosimilar candidate for Humira.
Portfolio Pulse from Benzinga Newsdesk
Alvotech's shares are trading lower following the FDA's complete response letter to the company's second application for AVT02, a biosimilar candidate for Humira.
June 29, 2023 | 8:39 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Alvotech's stock price is trading lower due to the FDA's complete response letter to the company's second application for AVT02.
The FDA's complete response letter is a setback for Alvotech's AVT02, a biosimilar candidate for Humira. This negative regulatory development has led to a decrease in Alvotech's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100